Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca completes enrollment of cancer drug trial

AstraZeneca completes enrollment of cancer drug trial

13th March 2008

AstraZeneca has announced today that it has completed patient enrollment in two phase III studies for its anti-cancer drug vandetanib.

The once-daily oral candidate is currently being investigated for the second-line treatment of non-small cell lung cancer (NSCLC) with the studies Zodiac and Zeal the second and third of four ongoing trials to complete enrollment.

Zodiac is a phase III study assessing the efficacy of vandetanib 100 mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of the first-line anti-cancer therapy.

Meanwhile, Zeal is a phase III study evaluating vandetanib 100 mg once-daily plus pemetrexed 500 mg/m2 (every three weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

“NSCLC is an area of high unmet medical need and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer,” said Dr Peter Langmuir, medical science director at AstraZeneca.

The Zest study, which is investigating vandetanib versus erlotinib, was the first phase III study of vandetanib to complete enrollment in November 2007.

Last month, AstraZeneca confirmed that its Horizon metastatic colorectal cancer programme was to move to phase III.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.